Novo Nordisk invests DKK1.5bn in new manufacturing facility in Denmark for haemophilia treatments

Published: 5-May-2015
Manufacturing Ingredients Finance

Will create around 100 new production and engineering jobs


Novo Nordisk has broken ground on a new DKK1.5bn (US$224m) facility which will produce active pharmaceutical ingredients for haemophilia products.

Approximately 100 new production and engineering jobs will be created at the new 7,500m2 facility in Kalundborg, Denmark where Novo Nordisk currently employs more than 2,800 people.

The company expects the facility to be approved and fully operational by 2020. It will produce APIs for NovoSeven, the Danish pharmaceutical company's recombinant treatment for patients with congenital haemophilia, which contains the active substance eptacog alfa, as well as future haemophilia products.

Henrik Wulff, Executive Vice President, Product Supply, Novo Nordisk, said: 'The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees.'

Established in 1969, the Kalundborg production site is Novo Nordisk's largest and has a total area of 1,000,000m2.

  • Companies:
  • Novo Nordisk Pharmatech
See more

You may also like

Finance

Novo Holdings completes acquisition of Catalent

Read more
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
  5. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Novo Holdings completes acquisition of Catalent

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
Manufacturing

Novo Nordisk invests DKK 8.5bn into new Danish modular production site

This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
Manufacturing

Novavax sells protein manufacturing facility to Novo Nordisk for $200m

Novo Nordisk's purchase of Novavax's Czech recombinant protein manufacturing facility will involve a full transfer of assets — including its workforce and associated support buildings
Manufacturing

Novo Nordisk acquires license to Ascendis Pharma's TransCon tech for up to $286m

Novo Nordisk will use the technology to develop, manufacture and commercialise therapeutics for metabolic and cardiovascular diseases
Manufacturing

Novo Nordisk teams up with Bio Farma and Indonesian government to enhance national diabetes drug accessibility

The collaboration will aim to enhance the availability of insulin and other diabetes drug products in Indonesia, where diabetes is one of the top three killers annually
Distribution

Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride

The two companies aim to expand the distribution of benzalkonium chloride within Europe
Manufacturing

BioInnovation adds eight early-stage companies to acceleration programme

Lomo, Novozymes and Amalus are all among the eight countries selected by BII to join its acceleration programme for early-stage companies looking to strike out into the pharmaceutical industry
Subscribe now